Skip to main content

Page of 2 next disabled
and
  1. Article

    Open Access

    Target discovery for T cell therapy: next steps to advance Immunotherapies

    Investigators from academia and industry gathered on August 14, 2014, in Boston at the Inaugural ImVacS conference entitled “Target Discovery for T Cell Therapy: Next Step to Advance Immunotherapies”. Novel ta...

    Adrian Bot, Joanna E Brewer, Zelig Eshhar in Journal for Immunotherapy of Cancer (2015)

  2. Article

    Open Access

    Toward cell transfer immunotherapy against patient-specific mutations in gastrointestinal cancers

    Eric Tran, Mojgan Ahmadzadeh, Alena Gros in Journal for ImmunoTherapy of Cancer (2014)

  3. Article

    Open Access

    Individual cultures of melanoma tumor infiltrating lymphocytes possess distinct patterns of reactivity with mutated antigens identified by whole exome sequencing of autologous tumors

    Jessica S Crystal, Yong Chen Lu, Yong Li in Journal for ImmunoTherapy of Cancer (2014)

  4. Article

    Open Access

    Melanoma-associated B cells are distinct from peripheral blood-derived B cells, and may serve as a source of tumor-targeting antibodies

    Daniel Abate-Daga, Theresa A Alexander, Evgeny Arons in Journal for ImmunoTherapy of Cancer (2013)

  5. No Access

    Article

    Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

    Identifying tumor-associated T cell epitopes can be laborious. Robbins et al. now report that they used whole-exome sequence data to identify mutated peptides from tumor antigens that are recognized by tumor-infi...

    Paul F Robbins, Yong-Chen Lu, Mona El-Gamil, Yong F Li, Colin Gross in Nature Medicine (2013)

  6. No Access

    Article

    Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression

    The therapeutic use of T cell receptor (TCR)-transduced peripheral blood lymphocytes (PBL) targeting tumor-associated antigens is emerging as a promising investigational treatment for patients with cancer. Ini...

    Jennifer A. Wargo, Paul F. Robbins, Yong Li in Cancer Immunology, Immunotherapy (2009)

  7. No Access

    Article

    Enforcement Authority and Vegetation Change at Kumbhalgarh Wildlife Sanctuary, Rajasthan, India

    Land cover change in protected areas is often associated with human use, especially illicit extraction, but the direction and spatial distribution of such effects and their drivers are poorly understood. We an...

    Paul F. Robbins, Anil K. Chhangani, Jennifer Rice in Environmental Management (2007)

  8. No Access

    Chapter

    Tumor Associated Antigens

    The results of an extensive series of studies that were first carried out in the early 1990s have revealed that human tumor reactive T cells recognize a diverse array of antigens. These include antigens expres...

    Paul F. Robbins in Analyzing T Cell Responses (2005)

  9. No Access

    Article

    MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells

    The unique antigen-presenting capabilities of dendritic cells (DCs) make them an attractive means with which to initiate an antitumor immune response. Using DCs transduced with tumor antigens for immunotherapy...

    J Mark Sloan, Michael H Kershaw, Christopher E Touloukian in Cancer Gene Therapy (2002)

  10. Article

    A listing of human tumor antigens recognized by T cells

    Nicolina Renkvist, Chiara Castelli, Paul F. Robbins in Cancer Immunology, Immunotherapy (2001)

  11. Article

    Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapies

    The MC-38 C57BL/6 mouse colon adenocarcinoma cell line has been transduced with a retroviral construct containing cDNA encoding the human carcinoembryonic antigen (CEA) gene [Robbins PF, Kantor JA, Salgaller M...

    Patricia Horan Hand, Paul F. Robbins in Cancer Immunology, Immunotherapy (1993)

Page of 2 next disabled